10.07.2012 - The European Commission has authorised the import of Monsanto’s soya which bears additional genes for a herbicide tolerance and an insecticide.
Just a few days after the European Food Safety Authority (EFSA) had approved the cultivation of genetically modified (GM) soya on European soils, the European Commission agreed on another soya matter. On 27 June, without public communication, the Commission authorised Monsanto Company’s genetically engineered soya Intacta RR2 Pro for import to the European Union. These soya plants harbour a combination of gene constructs that convey both tolerance for herbicides and resistance to insects. More specifically, Intacta is a combination of soys MON87701 and MON89788 which produce an insecticidal Bt protein and is tolerant to the herbicide glyphosate, respectively. It is the first time in the EU that gm-soya with stacked gene constructs has been allowed for usage in food and feed.
On 6 July the Brazilian Association of Seeds and Seedlings (ABRASEM) issued a statement „celebrating the opening of new doors to varieties of high technology seeds.“ Brazil is the main beneficiary of the authorisation as Monsanto’s soya is grown and harvested there. Europe is the second main destination of Brazilian soya exports, with China leading the chart. However, Intacta is not yet approved by China so that the European decision could very well be interpreted as trend-setting.
27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more